Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00557323 · ClinicalTrials.gov registry record
Long-term Effect of Lanthanum Carbonate on Bone
A clinical trial, sponsored by Shire.
- Completed
- Registry status
- 34
- Enrollment target
NCT00557323 is a clinical trial that has completed, run by Shire. The registered enrollment target is 34 participants.
The verdict
NCT00557323 has completed, sponsored by Shire.
- COMPLETED
- Registry status
- 34 participants
- Enrollment target
Study Summary
Patients enrolled in a previous study (SPD405-309), who were exposed to lanthanum carbonate (Fosrenol), were eligible to continue on any prescribed treatment for hyperphosphatemia, including lanthanum carbonate (Fosrenol), for an additional 5 years. Patients were being observed for any bone adverse events or other serious adverse events, as well as the collection of mortality data.
Interventions
- DRUG Lanthanum carbonate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2007-03-15 |
| Est. Completion | 2010-08-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00557323
The ClinicalTrials.gov registry entry for NCT00557323 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lanthanum carbonate is the first listed.
NCT00557323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00557323 about?
NCT00557323 is a clinical study titled "Long-term Effect of Lanthanum Carbonate on Bone". Patients enrolled in a previous study (SPD405-309), who were exposed to lanthanum carbonate (Fosrenol), were eligible to continue on any prescribed treatment for hyperphosphatemia, including lanthanum carbonate (Fosrenol), for an additional 5 years. Patients were being observed for any bone adverse ...
What is the current status of trial NCT00557323?
This trial is currently completed. The enrollment target is 34 participants. The study started on 2007-03-15. Estimated completion is 2010-08-31.
What interventions are being tested in trial NCT00557323?
The interventions under investigation include: Lanthanum carbonate (DRUG).
Who is sponsoring clinical trial NCT00557323?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.